Stay updated on RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision updated from v3.4.1 to v3.4.2, indicating a minor front-end update. No substantive study data or content changes are evident.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision from v3.4.0 to v3.4.1; no changes to study content or site functionality were observed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study details, contacts, locations, or outcomes were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a dedicated Locations section listing Beijing Municipality and Liaoning as study sites, replacing the previous location groupings.SummaryDifference0.2%

- Check106 days agoChange DetectedLast known status on the study record now shows 'Unknown status' with attribution to RemeGen Co., Ltd. and a verification timestamp (2023-11).SummaryDifference0.2%

Stay in the know with updates to RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page.